newsfilter
← Latest News
GlobeNewswire·

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

  • BioCryst Pharmaceuticals will report Q4 2025 financial results on February 26, 2026.
  • Management will host a conference call & webcast at 8:30 a.m. ET to discuss results & provide a corporate update.
  • The live call is accessible via 1-844-481-2942 for domestic callers or 1-412-317-1866 for international callers.
  • A live webcast & replay will be available in the investor section of www.biocryst.com.
  • BioCryst is a global biotechnology company focused on developing medicines for hereditary angioedema & other rare diseases.
  • The company commercializes ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor, while advancing a pipeline of small-molecule & injectable protein therapeutics.